# A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy

Source: https://onco.cc/trials/nct06742892/  
OnCo record `nct06742892` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HLX43 DOSE 1 in hepatocellular carcinoma, run by Shanghai Henlius Biotech, now recruiting.

## Summary

A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy is a phase 2 interventional study registered as NCT06742892 by Shanghai Henlius Biotech, with 90 participants planned, started 2025-03-03 and due to reach its primary completion in 2026-10-31. Interventions recorded: HLX43 DOSE 1, HLX43 DOSE 2 and HLX43 DOSE 3.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06742892
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate HLX43 (Anti-PD-L1 ADC) in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Failed or Intolerance to Standard Therapy
- Sponsor: Shanghai Henlius Biotech
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT06742892: https://clinicaltrials.gov/study/NCT06742892

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- companies: [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)

---
JSON: https://onco.cc/api/v1/entities/nct06742892.json